Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. The company is also developing Checkpoint kinase 1, a protein kinase in pre-clinical studies to inhibit tumor growth as single agents. In addition, it focuses on researching on Protocells, which are nanoparticles designed to enable the targeted delivery of various therapeutic agents, including nucleic acids, proteins, peptides, and small molecules, as well as to develop product candidates for the treatment of cancer. The company has a research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; Celldex Therapeutics, Inc. on a combined clinical trial of ONT-10 and varlilumab; and Adimab LLC for the discovery of novel antibodies against undisclosed immunotherapy targets in oncology. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for ONTY